Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems
暂无分享,去创建一个
[1] Ł. Matusiak. Profound consequences of hidradenitis suppurativa: a review , 2020, The British journal of dermatology.
[2] A. Ionescu,et al. Inter‐rater and intrarater agreement and reliability in clinical staging of hidradenitis suppurativa/acne inversa , 2019, The British journal of dermatology.
[3] A. Gottlieb,et al. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa , 2019, The British journal of dermatology.
[4] A. Vossen,et al. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient‐reported quality of life and objective disease severity assessment , 2019, The British journal of dermatology.
[5] A. Kimball,et al. Hidradenitis suppurativa/acne inversa: a practical framework for treatment optimization – systematic review and recommendations from the HS ALLIANCE working group , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] A. Gottlieb,et al. A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process , 2018, The British journal of dermatology.
[7] D. Presser,et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity , 2017, The British journal of dermatology.
[8] V. Piguet,et al. Development of core outcome sets in hidradenitis suppurativa: systematic review of outcome measure instruments to inform the process , 2016, The British journal of dermatology.
[9] G. Jemec,et al. New insights into the diagnosis of hidradenitis suppurativa: Clinical presentations and phenotypes. , 2015, Journal of the American Academy of Dermatology.
[10] S. Chimenti,et al. AISI: A New Disease Severity Assessment Tool for Hidradenitis Suppurativa. , 2015, Wounds : a compendium of clinical research and practice.
[11] C. Zouboulis,et al. Hidradenitis Suppurativa/Acne Inversa: Criteria for Diagnosis, Severity Assessment, Classification and Disease Evaluation , 2015, Dermatology.
[12] J. Lapins,et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.
[13] J. Rhodes,et al. The surface area of the hand and the palm for estimating percentage of total body surface area: results of a meta‐analysis , 2013, The British journal of dermatology.
[14] G. Jemec. Clinical practice. Hidradenitis suppurativa. , 2012, The New England journal of medicine.
[15] J. Lapins,et al. Interobserver variability of clinical scores in hidradenitis suppurativa is low , 2010, The British journal of dermatology.
[16] J. Szepietowski,et al. Hidradenitis suppurativa markedly decreases quality of life and professional activity. , 2010, Journal of the American Academy of Dermatology.
[17] O. Faye,et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. , 2008, Journal of the American Academy of Dermatology.
[18] A. Loundou,et al. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. , 2007, Journal of the American Academy of Dermatology.
[19] J. Lapins,et al. Suggestions for uniform outcome variables when reporting treatment effects in hidradenitis suppurativa , 2003, The British journal of dermatology.
[20] G. Jemec,et al. The prevalence of hidradenitis suppurativa and its potential precursor lesions. , 1996, Journal of the American Academy of Dermatology.
[21] E. Prens,et al. Hurley Staging Refined: A Proposal by the Dutch Hidradenitis Suppurativa Expert Group. , 2017, Acta dermato-venereologica.
[22] A. Alikhan. Hidradenitis Suppurativa. , 2016, JAMA dermatology.
[23] S. Kolenik. Dermatologic Surgery Principles and Practice , 1989, The Yale Journal of Biology and Medicine.